Belnacasan (VX-765) 化学構造
分子量: 509



Quality Control & MSDS


  • Compare Caspase Inhibitors
  • 研究分野



製品説明 Belnacasan (VX-765)は、0.8nMのKiによるインターロイキン変換酵素/カスパーゼ-1の強力で選択的な阻害剤です。
ターゲット Caspase-1
IC50 0.8 nM (Ki) [1]
In vitro試験 VX-765 is an orally absorbed prodrug of VRT-043198, which exhibits potent inhibition against ICE/caspase-1 and caspase-4 with Ki of 0.8 nM and less than 0.6 nM, respectively. And VRT-043198 also inhibits IL-1β release from both PBMCs and whole blood with IC50 of 0.67 μM and 1.9 μM, respectively. [1]
In vivo試験 In collagen-induced arthritis mouse model, VX-765 (200 mg/kg) inhibits LPS-induced IL-1β production by about 60%, and results in a dose-dependent, statistically significant reduction in the inflammation scores and effective protection from joint changes. [1] In vivo, VX-765 blocks kindling epileptogenesis in rats by preventing IL-1β increase in forebrain astrocytes without significant effect on afterdischarge duration. [2] In the mouse model of acute seizures, VX-765 (50 mg/kg-200 mg/kg) produces the anticonvulsant effect by delaying the time to onset of the first seizure and decreasing the number of seizures as well as their total duration by average 50% and 64%. [3] In adult rats with genetic absence epilepsy (GAERS), VX-765, after the 3rd drug injection, significantly reduces the cumulative duration and number of spike-and-wave discharges (SWDs) by 55% on average by selectively blocking IL-1β biosynthesis. [4]
臨床試験 VX-765 is currently in Phase II clinical trials in patients with treatment-resistant partial epilepsy.
特集 A potent and selective inhibitor of interleukin-converting enzyme/caspase-1.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Protease Enzyme Assays Enzyme inhibition is assayed by tracking of the rate of hydrolysis of an appropriate substrate labeled with either p-nitroaniline or aminomethyl coumarin (AMC) as follows: ICE/caspase-1, suc-YVAD-p-nitroanilide; caspase-4, Ac-WEHD-AMC; caspase-6, Ac-VEID-AMC; caspase-3, -7, -8, and -9, Ac-DEVD-AMC; and granzyme B, Ac-IEPD-AMC. Enzymes and substrates are incubated in a reaction buffer [10 mM Tris, pH 7.5, 0.1% (w/v) CHAPS, 1 mM dithiothreitol, and 5% (v/v) dimethyl sulfoxide] for 10 minutes at 37 °C. Glycerol is added to the buffer at 8% (v/v) for caspase-3, -6, and -9 and granzyme B to improve stability of enzymes. The rate of substrate hydrolysis is monitored using a fluorometer

動物実験: [1]

動物モデル Collagen-induced arthritis mouse model.
製剤 VX-765 is dissolved in 25% Cremophor EL.
投薬量 ≤200 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Belnacasan (VX-765) SDF
分子量 509


CAS No. 273404-37-8
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL warmed (196.46 mM)
エタノール 100 mg/mL warmed (196.46 mM)
<1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (S)-1-((S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-N-((2R,3S)-2-ethoxy-5-oxo-tetrahydrofuran-3-yl)pyrrolidine-2-carboxamide

カスタマーフィードバック (1)

Click to enlarge
Source , , Mucosal Immunol, 2015, 10.1038/mi.2015.44. Belnacasan (VX-765) purchased from Selleck
Method Western Blot
Cell Lines BMMs
Concentrations 50 µM
Incubation Time 1 h
Results Control experiments confirmed that both inhibitors MCC950 and VX-765 blocked cleavage and release of caspase-1 in response to CFT073 infection and LPS/nigericin stimulation in HMDMs and BMMs.



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related カスパーゼ 阻害剤&活性剤


    Z-DEVD-FMK is a specific, irreversible Caspase-3 inhibitor, and also shows potent inhibition on caspase-6, caspase-7, caspase-8, and caspase-10.

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • BV-6

    BV-6 is a SMAC mimetic, dual cIAP and XIAP inhibitor.

  • LCL161

    LCL161, a SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). Phase 2.

  • PAC-1


    Features:The first small molecule known to directly activate procaspase-3 to caspase-3.

  • Apoptosis Activator 2

    Apoptosis Activator 2は、カスパーゼを起動させます> シトクロムc依存的な方法で、そして、腫瘍細胞のアポトーシスを誘発します。



    Features:A key compound for apoptosis studies.

  • Tasisulam

    Tasisulam is an antitumor agent and an apoptosis inducer via the intrinsic pathway. Phase 3

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Kiof < 0.010 nM.

    Features:Re-engineered version of ABT-263 (Navitoclax).


Tags: Belnacasan (VX-765)を買う | Belnacasan (VX-765)供給者 | Belnacasan (VX-765)を購入する | Belnacasan (VX-765)費用 | Belnacasan (VX-765)生産者 | オーダーBelnacasan (VX-765) | Belnacasan (VX-765)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description